98%
921
2 minutes
20
ObjectiveThe prediction of early response in locally advanced nasopharyngeal carcinoma (LA-NPC) after concurrent chemoradiotherapy (CCRT) is important for determining the need for timely consolidation therapy. We developed a radiomic analysis of multi-sequences MR based on machine learning (ML) to assess early response in LA-NPC after CCRT.MethodsThis study retrospectively enrolled 104 LA-NPC patients, randomly divided into training (70%) and test (30%) cohorts. Radiomic features were extracted from five MR sequences (T1, T1C, T2, DWI, and ADC). Feature selection was performed using Pearson's correlation coefficient and LASSO regression to reduce redundancy. ML algorithms were compared to develop models, with suboptimal sequences excluded from the multi-sequence MR fusion model. A combined model integrating the fusion and clinical model was developed using logistic regression, and its diagnostic effectiveness was evaluated using receiver operating characteristic (ROC) analysis.ResultsIn the mono-sequence MR analysis, T1 demonstrated the lowest discriminative capacity (AUC = 0.505), followed by T2 (AUC = 0.738). Consequently, we developed a fusion model incorporating ADC, DWI, and T1C features while excluding T1 and T2. In the test cohort, the combined model outperformed both the clinical (AUC = 0.852) and fusion (AUC = 0.886) models, achieving superior effectiveness (AUC = 0.900). Shapley Additive Explanations (SHAP) analysis identified lbp_GrayLevelVariance_ADC as the most influential predictive feature.ConclusionsA combined model, which merges clinical and multi-sequences MR radiomics model, showed good performance for predicting early response of LA-NPC after CCRT.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062700 | PMC |
http://dx.doi.org/10.1177/00368504251338930 | DOI Listing |
Inflamm Bowel Dis
September 2025
IBD Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy.
Background: The infliximab (IFX) biosimilar, CT-P13, is available as an intravenous (IV) and subcutaneous (SC) formulation. Although current indications allow the transition from IV CT-P13 to SC CT-P13 after two IV administrations, some clinicians prefer to postpone switching until stable clinical remission has been achieved.
Methods: We evaluate the endoscopic response, treatment persistence, clinical remission, endoscopic remission, and safety profile after one year of treatment with IFX in patients switched from IV to SC after 6 weeks (early switch group) or after 6 months (late switch group).
Public Health Rep
September 2025
Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Objective: Rare diseases collectively affect approximately 30 million people in the United States. Despite advances in genomic medicine, early diagnosis is challenging because of limited awareness of, accessibility to, and disparities in health care resources. We assessed the real-world experiences of patients with rare diseases in Pennsylvania and evaluated the effect of delayed diagnosis on psychosocial and financial burdens.
View Article and Find Full Text PDFPlant Commun
September 2025
School of Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) Gatersleben, Seeland, Germany. Electronic address:
The coordination of floral developmental stages with the environment is important for reproductive success and the optimization of crop yields. The timing of different developmental stages contributes to final yield potential with optimal adaptation enabling development to proceed without being impacted by seasonal weather events, including frosts or end of season drought. Here we characterise the role of FLOWERING LOCUS T 3 (FT3) in hexaploid bread wheat (Triticum aestivum) during the early stages of floral development.
View Article and Find Full Text PDFMol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDFBrain Res
September 2025
Institute of Cognitive Neuroscience and Psychology, HUN-REN Research Centre for Natural Sciences, Hungary.
Identifying early predictors of language development is essential for understanding how infants acquire vocabulary during the first years of life. While previous studies have established the importance of infant-directed speech (IDS) and neural speech processing, this longitudinal study introduces a novel approach by combining EEG-based functional connectivity analysis and machine learning to assess the joint contribution of maternal and infant neural factors to language outcomes. Data were collected at birth and nine months, including maternal personality and speech characteristics, alongside infant EEG responses during speech processing.
View Article and Find Full Text PDF